A rational approach for discovering and validating cancer markers in very small samples using mass spectrometry and ELISA microarrays

Disease Markers

Volumn 20, Issue 3, 2004, Pages 135-148

  Zangar, Richard C ^a   Varnuma, Susan M ^a   Covington, Chandice Y ^b   Smith, Richard D ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biomarker; Mass spectrometry; Protein microarray; Proteomics

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ASPIRATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CLINICAL MEDICINE; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; DNA MICROARRAY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MASS SPECTROMETRY; NIPPLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE DIAGNOSIS; REVIEW; VALIDATION PROCESS;

EID: 4744341742     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/754640     Document Type: Review

References (63)

1. T.J. Herzog, New approaches for the management of cervical cancer, Gynecol Oncol 90 (2003), S22-S27.
2. F. Alexander-Sefre, U. Menon and I.J. Jacobs, Ovarian cancer screening, Hasp Med 63 (2002), 210-213.
3. U. Menon and I. Jacobs, Screening for ovarian cancer, Best Pract Res Clin Obstet Gynaecol 16 (2002), 469-482.
4. A.E. Guppy and G.J. Rustin, CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 7 (2002), 437-443.
5. J. Russo, P. Furmanski, R. Bradley, P. Wells and M.A. Rich, Differentiation of normal human mammary epithelial cells in culture: an ultrastructural study, Am J Anat 145 (1976), 57-77.
6. M.E. Rennison, S.E. Handel, C.J. Wilde and R.D. Burgoyne, Investigation of the role of microtubules in protein secretion from lactating mouse mammary epithelial cells, J Cell Sci 102(Pt 2) (1992), 239-247.
7. T. Wright and A. McGechan, Breast cancer: new technologies for risk assessment and diagnosis, Mol Diagn 7 (2003), 49-55.
8. E.R. Sauter, E. Ross, M. Daly, A. Klein-Szanto, P.F. Engstrom, A. Sorting, J. Malick and H. Ehya, Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk, Br J Cancer 76 (1997), 494-501.
9. L. Foretova, J.E. Garber, N.L. Sadowsky, S.J. Verselis, D.M. Joseph, A.F. Andrade, P.G. Gudrais, D. Fairclough and F.P. Li, Carcinoembryonic antigen in breast nipple aspirate fluid, Cancer Epidemiol Biomarkers Prev 7 (1998), 195-198.
10. K.K. Kaulsay, E.H. Ng, C.Y. Ji, G.H. Ho, T.C. Aw and K.O. Lee, Serum IGF-binding protein-6 and prostate specific antigen in breast cancer, Eur J Endocrinol 140 (1999), 164-168.
11. E.R. Sauter, M. Daly, K. Linahan, H. Ehya, P.F. Engstrom, G. Bonney, E.A. Ross, H. Yu and E. Diamandis, Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk, Cancer Epidemiol Biomarkers Prev 5 (1996), 967-970.
12. E.R. Sauter, J. Babb, M. Daly, P.P. Engstrom, H. Ehya, J. Malick and E. Diamandis, Prostate-specific antigen production in the female breast: association with progesterone, Cancer Epidemiol Biomarkers Prev 7 (1998), 315-320.
13. F. Mannello, M. Malatesta, M. Sebastiani, S. Battistelli and G. Gazzanelli, Molecular forms and ultrastructural localization of prostate-specific antigen in nipple aspirate fluids, Clin Chem 45 (1999), 2263-2266.
14. G.N. Papanicolaou, G.M. Bader, D.G. Holmquist and E.A. Falk, Cytologic evaluation of breast secretions, Ann N Y Acad Sci 30 (1956), 1409-1421.
15. R.M. Fleming, Cytological studies in lesions of the breast: findings in nipple secretions and aspirates from tumors, South Med J 48 (1955), 74-78.
16. E.B. King, D. Barren, M.C. King and N.L. Petrakis, Cellular composition of the nipple aspirate specimen of breast fluid. I. The benign cells, Am J Clin Palhol 64 (1975), 728-738.
17. E.B. King, D. Barrett and N.L. Petrakis, Cellular composition of the nipple aspirate specimen of breast fluid. II. Abnormal findings, Am J Clin Palhol 64 (1975), 739-748.
18. N.L. Petrakis, L. Mason, R. Lee, B. Sugimoto, S. Pawson and F. Catchpool, Association of race, age, menopausal status, and cerumen type with breast fluid secretion in nonlactating women, as determined by nipple aspiration, J Natl Cancer Inst 54 (1975), 829-834.
19. N.L. Petrakis, C.A. Maack, R.E. Lee and M. Lyon, Mutagenic activity in nipple aspirates of human breast fluid, Cancer Res 40 (1980), 188-189.
20. N.L. Petrakis, M.R. Wrensch, V.L. Ernster, R. Miike, E.B. King and W.H. Goodson, Prognostic-Significance of Atypical Epithelial Hyperplasia in Nipple Aspirates of Breast Fluid, Lancet 2 (1987), 505-505.
21. N.L. Petrakis, M.R. Wrensch, V.L. Ernster, R. Miike, J. Murai, N. Simberg and P.K. Siiteri, Influence of pregnancy and lactation on serum and breast fluid estrogen levels: implications for breast cancer risk, Int J Cancer 40 (1987), 587-591.
22. + Ratio, and Coloration, Breast Cancer Research and Treatment 13 (1989), 71-78.
23. N.L. Petrakis, Physiological, Biochemical, and Cytologic Aspects of Nipple Aspirate Fluid, Breast Cancer Research and Treatment 8 (1986), 7-19.
24. O.W. Sartorius, H.S. Smith, P. Morris, D. Benedict and L. Friesen, Cytologic evaluation of breast fluid in the detection of breast disease, J Natl Cancer Inst 59 (1977), 1073-1080.
25. S.M. Varnum, C.C. Covington, R.L. Woodbury, K. Petritis, L.J. Kangas, M.S. Abdullah, J.G. Pounds, R.D. Smith and R.C. Zangar, Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer, Breast Cancer Res Treat 80 (2003), 87-97.
26. N.L. Petrakis, R.E. Lee, R. Miike, M.E. Dupuy and M. Morris, Coloration of breast fluid related to concentration of cholesterol, cholesterol epoxides, estrogen, and lipid peroxides, Am J Clin Pathol 89 (1988), 117-120.
27. + Ratio, and Coloration, Breast Cancer Research and Treatment 13 (1989), 71-78.
28. F. Vizoso, L.M. Sanchez, I. Diez-Itza, L.M. Luz and C. Lopez-Otin, Factors affecting protein composition of breast secretions from nonlactating women, Breast Cancer Res Treat 23 (1992), 251-258.
29. M.R. Wrensch, N.L. Petrakis, L.D. Gruenke, V.L. Ernster, R. Miike, E.B. King and W.W. Hauck, Factors associated with obtaining nipple aspirate fluid: analysis of 1428 women and literature review, Breast Cancer Res Treat 15 (1990), 39-51.
30. D.P. Rose, B. Berke, L.A. Cohen and H. Lahti, A comparison of serum and breast duct fluid-immunoassayable prolactin and growth hormone with bioassayable lactogenic hormones in healthy women and patients with cystic breast disease, Cancer 60 (1987), 2761-2765.
31. D.P. Rose, Hormones and growth factors in nipple aspirates from normal women and benign breast disease patients, Cancer Detect Prev 16 (1992), 43-51.
32. C. Covington, A. Mitchell-Gieleghem, D. Lawson, I. Eto and C. Grubbs, Presence of carotenoid, an anticarcinogenic marker, in nipple aspirates postlactation, Adv Exp Med Biol 501 (2001), 143-152.
33. L.M. Nantais-Smith, C.Y. Covington, B.A. Nordstrom-Klee, C.J. Grubbs, I. Eto, D.M. Lawson, B.A. Pieper and L.L. Northouse, Differences in plasma and nipple aspirate carotenoid by lactation status, Nurs Res 50 (2001), 172-177.
34. N.L. Anderson and N.G. Anderson, The human plasma proteome: history, character, and diagnostic prospects, Mol Cell Proteomics 1 (2002), 845-867.
35. R.D. Smith, Y. Shen and K. Tang, Ultra-sensitive and quantitative analyses from combined separations-mass spectrometry for the characterization of proteomes, Accounts Chem Res 37 (2004), 269-278.
36. Y. Shen, J.M. Jacobs, D.G. Camp, R. Fang, R.J. Moore and R.D. Smith, High efficiency SCXLC/RPLC/MS/MS for high dynamic range characterization of the human plasma proteome, Anal Chem 16 (2004), 144-154.
37. M.E. Belov, G.A. Anderson, N.H. Angell, Y. Shen, N. Tolic, H.R. Udseth and R.D. Smith, Dynamic range expansion applied to mass spectrometry based on data-dependent selective ion ejection in capillary liquid chromatography fourier transform ion cyclotron resonance for enhanced proteome characterization, Anal Chem 73 (2001), 5052-5060.
38. L. Pasa-Tolic, R. Harkewicz, G.A. Anderson, N. Tolic, Y. Shen, R. Zhao, B. Thrall, C. Masselon and R.D. Smith, Increased proteome coverage for quantitative peptide abundance measurements based upon high performance separations and DREAMS FTICR mass spectrometry, J Am Soc Mass Spectrom 13 (2002), 954-963.
39. R.D. Smith, Evolution of ESI-mass spectrometry and Fourier transform ion cyclotron resonance for proteomics and other biological applications, Internation Journal of Mass Spectrometry 200 (2000), 509-544.
40. T.P. Conrads, G.A. Anderson, T.D. Veenstra, L. Pasa-Tolic and R.D. Smith, Utility of accurate mass tags for proteome-wide protein identification, Anal Chem 72 (2000), 3349-3354.
41. M.S. Lipton, L. Pasa-Tolic', G.A. Anderson, D.J. Anderson, D.L. Auberry, J.R. Battista, M.J. Daly, J. Fredrickson, K.K. Hixson, H. Kostandarithes, C. Masselon, L.M. Markillie, R.J. Moore, M.F. Romine, Y. Shen, E. Stritmatter, N. Tolic', H.R. Udseth, A. Venkateswaran, K.K. Wong, R. Zhao and R.D. Smith, Global analysis of the Deinococcus radiodurans proteome by using accurate mass tags, Proc Natl Acad Sci USA 99 (2002), 11049-11054.
42. Y. Shen, C.D. Masselon, N. Tolic, L. Pasa-Tolic, H.K. Hixson, J.M. Jacobs and R.D. Smith, Probing the dynamic range of high resolution RPLC/FTICR MS proteomics measurements, Anal Chem (2004), In press.
43. T.P. Conrads, K. Alving, T.D. Veenstra, M.E. Belov, G.A. Anderson, D.J. Anderson, M.S. Lipton, L. Pasa-Tolic, H.R. Udseth, W.B. Chrisler, B.D. Thrall and R.D. Smith, Quantitative analysis of bacterial and mammalian proteomes using a combination of cysteine affinity tags and 15N-metabolic labeling, Anal Chem 73 (2001), 2132-2139.
44. M.A. Moseley, Current trends in differential expression proteomics: isotopically coded tags, TRENDS in Biotechnology 19 (2001), S10-S16.
45. S.P. Gygi, B. Rist, S.A. Gerber, F. Turecek, M.H. Gelb and R. Aebersold, Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, Nat Biotechnol 17 (1999), 994-999.
46. A.I. Nepomuceno, D.C. Muddiman, H.R. Bergen, J.R. Craighead, M.J. Burke, P.E. Caskey and J.A. Allan, Dual electrospray ionization source for confident generation of accurate mass tags using liquid chromatography Fourier transform ion cyclotron resonance mass spectrometry, Analytical Chemistry 75 (2003), 3411-3418.
47. A. Ducret, O. Van, I, J.K. Eng, J.R. Yates, III and R. Aebersold, High throughput protein characterization by automated reverse-phase chromatography/electrospray tandem mass spectrometry, Protein Sci 7 (1998), 706-719.
48. K. Petritis, L.J. Kangas, P.L. Ferguson, G.A. Anderson, L. Pasa-Tolic', M.S. Lipton, K.J. Auberry, E. Stritmatter, Y. Shen, R. Zhao and R.D. Smith, Use of artificial neural networks for the prediction of peptide liquid chromatography elution times in proteome analyses, Anal Chem 75 (2003), 1039-1048.
49. W.X. Wang, H.H. Zhou, H. Lin, S. Roy, T.A. Shaler, L.R. Hill, S. Norton, P. Kumar, M. Anderle and C.H. Becker, Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards, Analytical Chemistry 75 (2003), 4818-4826.
50. O. White, J.A. Eisen, J.F. Heidelberg, E.K. Hickey, J.D. Peterson, R.J. Dodson, D.H. Haft, M.L. Gwinn, W.C. Nelson, D.L. Richardson, K.S. Moffat, H. Qin, L. Jiang, W. Pamphile, M. Crosby, M. Shen, J.J. Vamathevan, P. Lam, L. McDonald, T. Utterback, C. Zalewski, K.S. Makarova, L. Aravind, M.J. Daly and C.M. Fraser, Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1, Science 286 (1999), 1571-1577.
51. M.D. Ermolaeva, H.G. Khalak, O. White, H.O. Smith and S.L. Salzberg, Prediction of transcription terminators in bacterial genomes, J Mol Biol 301 (2000), 27-33.
52. R.D. Smith, G.A. Anderson, M.S. Lipton, L. Pasa-Tolic, Y. Shen, T.P. Conrads, T.D. Veenstra and H.R. Udseth, An accurate mass tag strategy for quantitative and high-throughput proteome measurements, Proteomics 2 (2002), 513-523.
53. J.S. MacNeil, Making FT/MS matter, Genome Tech 34 (2003), 34-40.
54. J.N. Adkins, S.M. Varnum, K.J. Auberry, R.J. Moore, N.H. Angell, R.D. Smith, D.L. Springer and J.G. Pounds, Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry, Mol Cell Proteomics 1 (2002), 947-955.
55. M. Malatesta, F. Mannello, G. Bianchi, M. Sebastiani and G. Gazzanelli, Biochemical and ultrastructural features of human milk and nipple aspirate fluids, J Clin Lab Anal 14 (2000), 330-335.
56. P. Klein, E. Glaser, L. Grogan, M. Keane, S. Lipkowitz, P. Soballe, L. Brooks, J. Jenkins, S.M. Steinberg, D.M. DeMarini and I. Kirsch, Biomarker assays in nipple aspirate fluid, Breast J 7 (2001), 378-387.
57. A.J. Link, J. Eng, D.M. Schieltz, E. Carmack, G.J. Mize, D.R. Morris, B.M. Garvik and J.R. Yates, III, Direct analysis of protein complexes using mass spectrometry, Nat Biotechnol 17 (1999), 676-682.
58. M.P. Washburn, D. Wolters and J.R. Yates, III, Large-scale analysis of the yeast proteome by multidimensional protein identification technology, Nat Biotechnol 19 (2001), 242-247.
59. R.L. Woodbury, S.M. Vamum and R.C. Zangar, Elevated HGF levels in sera from breast cancer patients detected using a protein rnicroarray ELISA, Journal of Proteome Research 1 (2002), 233-237.
60. S.M. Varnum, R.L. Woodbury and R.C. Zangar, A protein rnicroarray ELISA for screening biological fluids, Methods Mol Biol (2003), In Press.
61. W.H. McDonald and J.R. Yates, III, Shotgun proteomics: integrating technologies to answer biological questions, Curr Opin Mol Ther 5 (2003), 302-309.
62. S.P. Gygi, G.L. Corthals, Y. Zhang, Y. Rochon and R. Aebersold, Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology, Proc Natl Acad Sci USA 97 (2000), 9390-9395.
63. R.P. Ekins, Ligand assays: from electrophoresis to miniaturized microarrays, Clin Chem 44 (1998), 2015-2030.